BOSTON, July 3, 2019 /PRNewswire-PRWeb/ — NanoFUSE Biologics is pleased to announce its continued global expansion into Asia marked by a successful procedure performed by the Thai Neurosurgeon, Dr. Teera Tangviriyabiaboon, at Prasart Neurological Institute. Dr. Teera Tangviriyabiaboon completed the procedure on an 80-year-old female patient suffering from degenerative spine disease and osteoporosis. The patient failed conservative treatments prior to undergoing surgery.
NanoFUSE Biologics is the only bioactive glass that is FDA-cleared to be combined with DBM. Bioactive glass has been clinically proven in orthopedics for over 30 years, but NanoFUSE Biologics is the first to use bioactive glass to create a revolutionary and patented biologic.
Jake Lubinski, President of NanoFUSE said, “NanoFUSE is clinically proven and reduces the need for autograft. We’re proud to offer the highest quality of DBM and synthetic biologics to treat patients in Thailand. The recent release of our 100% fully synthetic bioactive glass strip, NanoSTRIP positions NanoFUSE to be the worldwide leader in bioactive glass and synthetic biologics.”
Dr. Teera Tangviriyabiaboon spoke to the advantages of NanoFUSE after the operation stating, “NanoFUSE was easy to use and it is expected to maximize success of spine fusion as the only approved DBM and bioactive glass combination biologic.”
Thailand is one of the fastest aging countries in Asia and is well-known for medical tourism. NanoFUSE has been enthusiastically welcomed by spine neurosurgeons and orthopedic surgeons in Thailand who have been waiting for a premium quality DBM and synthetic biologic to be launched in their country.
Dr. Tangviriyabiaboon is a spine neurosurgeon specializing in complex spine reconstruction and vertebral tumor surgery, as well as all aspects of adult and pediatric spine surgery.
About NanoFUSE Biologics
NanoFUSE is the synergistic blend of osteoinductive DBM combined with the osteostimulative properties of bioactive glass. NanoFUSE is the only FDA-cleared combination of DBM and bioactive glass and is indicated for use in orthopedic surgery. NanoFUSE Biologics is a KICVentures portfolio company and is distributed by SpineFrontier.
KICVentures is a private investment holding company founded by Harvard-trained Orthopedic Surgeon & Professor Dr. Kingsley R. Chin, who brings unique experience at the intersection of medicine, business and information technology. KICVentures is equipped with a strong advantage in identifying niche healthcare opportunities and has a proven track-record of building the most disruptive spine technology portfolio, including AxioMed, NanoFUSE and SpineFrontier. It has headquarters in Boston, MA.